SCHEMBL4459931

SCHEMBL4459931

O=[N+]([O-])c1ccc2nc3n(c2c1)CCCC3

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.51
ALDH1A1 P00352 7/20 0.50
KMT2A Q03164 3/20 0.50
MITF O75030 2/20 0.50
LMNA P02545 1/20 0.50
HTT P42858 1/20 0.50
PAX8 Q06710 1/20 0.49
ATM Q13315 1/20 0.49
RAB9A P51151 3/20 0.48
NPC1 O15118 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
POLB P06746 1/20 0.48
ACHE P22303 3/20 0.47
MAPK1 P28482 1/20 0.47
APOBEC3A P31941 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47
MEN1 O00255 2/20 0.46
HPGD P15428 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL840476 0.84 MAPT (0.66) MAPTALDH1A1KMT2AMITFLMNA
SCHEMBL2050003 0.79 KMT2A (0.60) MAPTALDH1A1KMT2AMITFLMNA
SCHEMBL830582 0.78 ALDH1A1 (0.50) MAPTALDH1A1LMNARAB9ANPC1
SCHEMBL11083539 0.78 ALDH1A1 (0.64) MAPTALDH1A1KMT2AMITFLMNA
SCHEMBL10849420 0.76 TDP1 (0.64) MAPTALDH1A1KMT2AMITFLMNA
SCHEMBL24329596 0.75 MEN1 (0.51) ALDH1A1KMT2ALMNASMN1; SMN2POLB
SCHEMBL12476436 0.75 ALDH1A1 (0.58) ALDH1A1KMT2ALMNASMN1; SMN2POLB
SCHEMBL24330982 0.75 SMN1; SMN2 (0.63) MAPTALDH1A1KMT2ALMNASMN1; SMN2
SCHEMBL24329884 0.75 MEN1 (0.51) MAPTALDH1A1KMT2ALMNAHTT
SCHEMBL17531765 0.73 MAPT (0.43) MAPTALDH1A1KMT2ALMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504412-B2 Imidazopyridine derivatives BANYU PHARMACEUTICALS, CO., LTD. (JP) 2009-03-17 US disclosed
US-20080200494-A1 Imidazopyridine Derivatives MSD K.K. (JP) 2008-08-21 US disclosed
EP-1657242-A1 IMIDAZOPYRIDINE DERIVATIVES Banyu Pharmaceutical Co., Ltd. (JP) 2006-05-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200494-A1 Imidazopyridine Derivatives MC1R, MC3R, MC5R MAPT 3076/4885ALDH1A1 1277/4885KMT2A 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.